Our findings suggest that the increased rate of HER-2/neu positive DCIS compared with breast cancer may reflect the loss of HER-2/neu during tumorigenesis in premalignant cells where IFN-γ signaling pathway is active. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.